New strategies for prevention of ischemic stroke: The LIFE study

被引：4
作者：
Harold P. Adams
机构：
[1] Department of Neurology, University of Iowa, Iowa City, IA 52246
来源：
Current Neurology and Neuroscience Reports | 2003年 / 3卷 / 1期
关键词：
Ischemic Stroke; Atenolol; Left Ventricular Hypertrophy; Losartan; Stroke Prevention;
D O I：
10.1007/s11910-003-0036-7
中图分类号：
学科分类号：
摘要：
New strategies to lower the risk of stroke among high-risk persons are being developed. Therapies such as cholesterol-lowering medications and newer antihypertensive agents appear to complement traditional antithrombotic drugs and surgical procedures. Of particular interest is the use of the newer angiotensin-converting enzyme (ACE) inhibitors, which appear to have an effect on stabilizing the vascular endothelium. The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：46 / 51
页数：5
相关论文
共 37 条
[1]  
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, pp. 71-86, (2002)
[2]  
Blauw G.J., Lagaay A.M., Smelt A.H., Westendorp R.G., Stroke, statins, and cholesterol, Stroke, 28, pp. 946-950, (1997)
[3]  
Byington R.P., Jukema J.W., Salonen J.T., Et al., Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program, Circulation, 922, pp. 2419-2425, (1995)
[4]  
Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H., Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials, JAMA, 278, pp. 313-321, (1997)
[5]  
Crouse J.R., Byington R.P., Furberg C.D., HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data, Atherosclerosis, 138, pp. 11-24, (1998)
[6]  
Yusuf S., Sleight P., Pogue J., Et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N. Engl. J. Med., 342, pp. 145-153, (2000)
[7]  
Randomised trial of a perindopril-based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack, Lancet, 358, pp. 1026-1027, (2001)
[8]  
Neal B., MacMahon S., Chapman N., Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials, Lancet, 356, pp. 1955-1964, (2000)
[9]  
Dahlof B., Devereux R.B., Kjeldsen S.E., Et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol, Lancet, 359, pp. 995-1003, (2002)
[10]  
Lindholm L.H., Ibsen H., Dahlof B., Et al., Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol, Lancet, 359, pp. 1004-1010, (2002)
1234